Leqselvi (deuruxolitinib) / Sun Pharma - LARVOL DELTA

Pediatric Alopecia Areata and JAK Inhibitors: Bridging the Gap Between Evidence and Practice. (PubMed, J Am Acad Dermatol) - "Despite this, emerging evidence and clinical experience demonstrate meaningful hair regrowth in pediatric patients treated with several JAKis, including abrocitinib, baricitinib, deuruxolitinib, ritlecitinib, ruxolitinib, tofacitinib, and upadacitinib, with generally favorable safety profiles. Limitations include heterogeneous outcome reporting between various reports and studies. Overall, this clinical review synthesizes current evidence and clinical experience to provide practical guidance on JAKi selection, dosing, safety monitoring, and key considerations for implementing these therapies in pediatric AA."

Journal • Review • Alopecia • Eosinophilia • Gastrointestinal Disorder • Immunology • Pediatrics

Efficacy of deuruxolitinib in patients with severe alopecia areata by baseline nail involvement: Pooled post hoc analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials (EADV 2026) - No abstract available

Clinical • P3 data • Retrospective data • Alopecia • Immunology

Efficacy of deuruxolitinib in patients with severe alopecia areata by baseline eyebrow involvement: Pooled post hoc analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials (EADV 2026) - No abstract available

Clinical • P3 data • Retrospective data • Alopecia • Immunology

Maintenance of hair regrowth following dose reduction or discontinuation of deuruxolitinib in patients with severe alopecia areata: A Phase 2 randomized study (EADV 2026) - No abstract available

Clinical • P2 data • Alopecia • Immunology

Deuruxolitinib improves scalp hair regrowth in adults with severe alopecia areata: Long-term efficacy results from an open-label extension study (EADV 2026) - No abstract available

Clinical • Alopecia • Immunology

Efficacy of deuruxolitinib in patients with severe alopecia areata by baseline eyelash involvement: Pooled post hoc analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials (EADV 2026) - No abstract available

Clinical • P3 data • Retrospective data • Alopecia • Immunology

Efficacy of deuruxolitinib in patients with severe alopecia areata by baseline alopecia areata episode duration: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials (EADV 2026) - No abstract available

P3 data • Retrospective data • Alopecia • Immunology

Safety of deuruxolitinib with up to 2 years of treatment in adults with severe alopecia areata: Long-term results from an open-label extension study (EADV 2026) - No abstract available

Clinical • Alopecia • Immunology

A safety review of jak inhibitors for managing alopecia areata. (PubMed, Expert Opin Drug Saf) - "This review evaluates the safety of JAK inhibitors used for AA in adults, with emphasis on baricitinib, ritlecitinib, and deuruxolitinib, alongside relevant evidence for other JAK inhibitors. Current evidence suggests that serious adverse outcomes are uncommon in appropriately selected adults with AA and that risks observed in older, comorbidity-enriched rheumatologic populations should not be directly extrapolated to AA. Future management will increasingly depend on individualized risk stratification, long-term disease-specific safety data, and agent-specific rather than class-wide assessment."

Adverse events • Journal • Review • Alopecia • Cardiovascular • Immunology • Infectious Disease • Oncology • Rheumatology

Dose optimization of deuruxolitinib in adults with alopecia areata: A phase 2 randomized trial. (PubMed, J Am Acad Dermatol) - P2 | "Deuruxolitinib 8 mg BID was associated with greater improvements in scalp hair regrowth vs deuruxolitinib 16 mg QD."

Journal • P2 data • Alopecia • Immunology • JAK1

Alopecia areata: Emerging therapies and up-to-date management strategies. (PubMed, J Am Acad Dermatol) - "First-line therapy for mild-to-moderate AA (SALT<50) includes topical or intralesional corticosteroids, often with topical or oral minoxidil...Selection among baricitinib, ritlecitinib, and deuruxolitinib is guided by patient age, safety considerations, comorbidities, laboratory monitoring, and insurance coverage...Adjunctive and alternative therapies include topical immunotherapy, systemic immunosuppressants, emerging biologic/targeted therapies, and procedural modalities, such as platelet-rich plasma, laser- and light-based therapies, and microneedling. This review synthesizes current evidence on AA treatment and offers a practical, contemporary framework for AA management."

Journal • Review • Alopecia • Immunology

Dupilumab and ritlecitinib combination therapy in a patient with alopecia totalis and atopic disease. (PubMed, JAAD Case Rep) - No abstract available

Journal • Alopecia • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Alopecia Areata: Current and Emerging Therapies. (PubMed, Drugs) - "Targeted JAK inhibitors have emerged as the first reliably effective systemic treatments for severe AA, leading to the regulatory approval of baricitinib, ritlecitinib, and deuruxolitinib. A substantial proportion of patients fail to achieve near-complete or complete regrowth, all approved medicines belong to the same drug class, and there are no agents approved for pre-adolescents. This review provides a critical overview of approved and emerging therapies for AA, integrating clinical trial data, comparative efficacy analyses, and real-world evidence, while highlighting current limitations and future directions."

Journal • Review • Alopecia • Immunology • Pediatrics • IFNG • IL15

Response to Hermosa-Gelbard et al., "Switching from deuruxolitinib to baricitinib in alopecia areata: a real-world cohort of 36 patients". (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Real-world evidence • Alopecia • Immunology

Switching from deuruxolitinib to baricitinib in alopecia areata: a real-world cohort of 36 patients. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Real-world evidence • Alopecia • Immunology

Success of Deuruxolitinib (Leqselvi™) in Extensively Treatment-Resistant Alopecia Universalis: A Case Report. (PubMed, Cureus) - "We describe a 30-year-old man with a 23-year history of AU who demonstrated minimal response to multiple prior therapies, including tofacitinib (pan-JAK inhibitor) and ritlecitinib (JAK3/TEC inhibitor), without meaningful scalp, eyebrow, or eyelash regrowth. Following six months of treatment with deuruxolitinib, the patient experienced his first clinically significant regrowth, limited to the eyebrows and eyelashes, while scalp involvement remained largely unchanged. This case highlights the potential for site-specific hair regrowth in longstanding, treatment-refractory AU and suggests that eyebrow and eyelash regrowth may occur even in the absence of substantial scalp hair recovery."

Journal • Alopecia • Immunology • JAK3

Comparative efficacy of Janus kinase inhibitors in severe alopecia areata: a network meta-analysis based on randomized controlled trials. (PubMed, Postgrad Med J) - "The efficacy of JAK inhibitors in the treatment of severe AA is definitive, and all possess a dose-dependent effect. This study provides valuable insights for clinicians in selecting appropriate pharmacological interventions for severe AA. Key messages What is already known on this topic: Alopecia areata is an autoimmune disorder characterized by patchy hair loss on the scalp. Previous studies have demonstrated that JAK inhibitors can effectively treat alopecia areata, but research comparing the efficacy of different JAK inhibitors is lacking. What this study adds: This study established a ranking of efficacy for different JAK inhibitors in treating severe alopecia areata, providing a reference for selecting clinical treatment regimens. How this study might affect research, practice, or policy: Future studies are needed to directly compare the efficacy of different JAK inhibitors in treating alopecia areata. This will provide more reliable evidence for formulating..."

Journal • Retrospective data • Alopecia • Immunology

A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata. (PubMed, Adv Ther) - "Our study demonstrated that, regarding JAK inhibitor treatment of AA, clinicians preferred options with higher efficacy and shorter time to onset regardless of once-daily or twice-daily dosing."

Journal • Alopecia • Dermatology • Immunology

The dose matters: Oral tofacitinib dose escalation or switching to deuruxolitinib for recalcitrant alopecia universalis and totalis, a retrospective case series. (PubMed, JAAD Case Rep) - No abstract available

Journal • Retrospective data • Alopecia • Immunology

Deuruxolitinib: New Approval. (PubMed, Clin Drug Investig) - "Deuruxolitinib (LEQSELVI), a deuterated analogue of the Janus kinase (JAK) 1/2 inhibitor ruxolitinib, is being developed by Sun Pharmaceuticals Industries for the treatment of alopecia areata. Additionally, in March 2026, deuruxolitinib received approval in the same indication in the UK. This article summarizes the milestones in the development of deuruxolitinib leading to the approval for severe alopecia areata in adults."

Journal • Review • Alopecia • Immunology

THRIVE-AAJP: Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata (clinicaltrials.gov) - P3 | N=78 | Recruiting | Sponsor: Sun Pharma Japan Limited | Not yet recruiting ➔ Recruiting

Enrollment open • Alopecia • Dermatology • Immunology

Large-scale meta-analysis of infection risk with JAK-STAT inhibitors in 29,000 patients. (PubMed, J Eur Acad Dermatol Venereol) - "This meta-analysis provides a comprehensive assessment of the risk of infection associated with JAK-STAT inhibitors in IMIDs of the skin. Although overall safety is acceptable, clinicians should be aware of the higher infection risk of influenza and herpes zoster and should consider vaccination and preventive strategies for high-risk patients with atopic dermatitis. The main limitation is that the included studies involved highly selected populations with few comorbidities and short follow-up."

Journal • Retrospective data • Review • Alopecia • Atopic Dermatitis • Dermatitis • Dermatology • Herpes Zoster • Immunology • Infectious Disease • Inflammation • Influenza • Pulmonary Disease • Respiratory Diseases • Varicella Zoster • Vitiligo

THRIVE-AAJP: Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata (clinicaltrials.gov) - P3 | N=78 | Not yet recruiting | Sponsor: Sun Pharma Japan Limited

New P3 trial • Alopecia • Dermatology • Immunology

Alopecia areata: Mechanisms, targeted therapies, and translational challenges. (PubMed, Curr Opin Pharmacol) - "The clinical approval of JAK inhibitors-baricitinib, ritlecitinib, and deuruxolitinib-represents a major therapeutic milestone, validating targeted immune modulation as an effective strategy for moderate-to-severe AA. This review critically synthesizes current evidence on AA pathogenesis and therapy, with particular emphasis on unresolved controversies, translational barriers, and clinical implications. By integrating mechanistic insights with emerging clinical data, the article highlights priorities for future research, including biomarker development, precision medicine approaches, and strategies aimed at achieving durable disease control rather than transient immune suppression."

Journal • Review • Alopecia • Immune Modulation • Immunology • CD8 • IFNG • NKG2D

Therapeutic update on alopecia areata: a critical review of standard and emerging targeted therapies. (PubMed, Inflammopharmacology) - "Targeted therapies, specifically JAK inhibitors, have transformed the prognosis for severe AA. However, high costs, relapse post-discontinuation, and long-term safety profiles necessitate careful patient selection. Future management must integrate advanced pharmacotherapy with holistic lifestyle interventions and personalized medicine based on prognostic biomarkers."

IO biomarker • Journal • Review • Alopecia • CNS Disorders • Immunology • Infectious Disease • Respiratory Diseases • Sleep Disorder • IFNG • IL15 • LEP